In this study, we constructed a PBPK model of SGLT2 inhibitors, combined with a mathematical model of UGE, to simulate and predict changes in the PK and PD of SGLT2 inhibitors in healthy subjects and patients with T2DM and renal insufficiency. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.